Oncology nurses are integral to the success of ECP, as they provide ongoing education and psychosocial support to patients. Hear expert insights on how GVHD research is evolving as investigators evaluate new prevention and treatment strategies. Before axatilimab, targeting the CSF-1R pathway was not previously studied in cGVHD. New research and therapeutic approaches are challenging long-held beliefs about this type of graft. The ongoing trial is evaluating if MaaT033 can increase survival by preventing complications such as GVHD. It's critical for oncology nurses to encourage these patients to monitor their blood pressure at home. Renal toxicity occurs in approximately 75% of all patients who receive allogeneic stem cell transplants. A new study highlights the importance of effective management and close monitoring of GVHD. Learn how an early intervention with oral mucosal barrier protective agents can help patients with chronic oral GVHD. Learn what a team in Sweden found when they began offering home care after allogeneic HSCT for patients who lived nearby. Learn how oncology nurses can address the challenges associated with early detection, diagnosis, and management. It's critical for oncology nurses understand and recognize the 3 atypical lung cGVHD conditions. A small study evaluated the ROCK2 inhibitor for treatment of ocular GVHD because corneal epithelial cells express ROCK2. Oncology nurses must familiarize themselves with CNS and PNS cGVHD to improve patient outcomes. With better understanding of CNS cGVHD, oncology nurses can help ensure early recognition and reporting. In the United States, 33%-50% of patients receiving an allogeneic transplant develop acute GVHD. There are 5 types of immune-mediated cytopenias, each with provisional diagnostic criteria. Nurses have a critical role in managing cGVHD-related serositis, including patient assessment, direct care, and education. Researchers presented real-world data on the cGVHD treatment during the EHA 2024 Congress. Certain predictive markers may help identify patients who "experience significant benefits" from upfront use of this therapy.